A variety of other kinase inhibitors are used or in trials for hematologic cancers (e.g. PI3K inhibitors like idelalisib, BCL2 inhibitor venetoclax, MEK inhibitors in trials for certain leukemias). This evidence concerns the gene MAP2K7 and leukemia.